composition comprising a carboxamide derivative for use in endoparasite control

专利摘要:
endoparasite control agent and method for controlling endoparasites. an endoparasite control agent comprising a carboxamide derivative represented by the general formula (i): or a salt thereof as an active ingredient, and a method for controlling endoparasites comprising administering orally or parenterally the endoparasite control agent are provided.
公开号:BR112013021337B1
申请号:R112013021337
申请日:2012-03-01
公开日:2019-09-03
发明作者:Suwa Akiyuki；Kita Kiyoshi
申请人:Nihon Nohyaku Co Ltd；Univ Tokyo；
IPC主号:

专利说明:

COMPOSITION UNDERSTANDING A CARBOXAMIDE DERIVATIVE FOR USE IN THE CONTROL OF ENDOPARASITES
FIELD OF THE INVENTION
The present invention relates to an endoparasite control agent comprising a carboxamide derivative or a salt thereof as an active ingredient, and a method for controlling endoparasites, comprising administering the endoparasite control agent orally or parenterally.
BACKGROUND OF THE INVENTION
Certain types of carboxamide derivatives have been known to have microbicidal activity (see Patent Literature 1 to 12). However, there is no description indicating that these compounds described in the literature are effective against endoparasites in animals such as mammals and birds. In addition, it is known that certain types of carboxamide derivatives are effective against nematodes that can damage agricultural products (see Patent Literature 4 or 5), but there is no specific disclosure about any effect against endoparasites in animals. In addition, it is reported that compounds that inhibit succinate-ubiquinone reductase (mitochondrial complex II), which is one of the respiratory enzymes of endoparasites, can serve as an endoparasite control agent (see Non-Patent Literature 1).
CITATION LIST
Patent Literature
Patent Literature 1: JP-A 01-151546
Patent Literature 2: WO 2007/060162
Patent Literature 3: JP-A 53-9739
Patent Literature 4: WO 2007/108483
Patent Literature 5: WO 2008/126922
Patent Literature 6: WO 2008/101975
Patent Literature 7: WO 2008/101976
Patent Literature 8: WO 2008/003745
Patent Literature 9: WO 2008/003746
Patent Literature 10: WO 2009/012998
Patent Literature 11: WO 2009/127718
Patent Literature 12: WO 2010/106071
Non-patent literature
Non-patent literature 1:
Kiyoshi Kita, “Kansen (Infection)”, Winter 2010, Vol. 40-4, 310-319
Petition 870190055407, of 6/14/2019, p. 14/38
2/34
SUMMARY OF THE INVENTION
TECHNICAL PROBLEM
Generally, parasitosis is caused by parasites that have infected and resided in host animals, and examples of the parasites include unicellular protists (protozoa), helminths and multicellular arthropods. It is reported that the incidence of parasitosis in Japan has been noticeably reduced by the improvement of environmental hygiene, but on a global scale, particularly in developing countries, parasitosis still prevails widely and causes great damage. In recent years, there has been an increasing trend in the incidence of parasitic infection due to the introduction of infectious sources through long or short term travelers from abroad, intake of food imports, intake of raw meat and fish meat that are more available thanks to advances in freezing and logistics technologies, etc., and also in the incidence of pet parasitosis, etc. Another problem is that immunodeficiency caused by mass administration of immunosuppressants, cancer drugs, etc. or for AIDS etc. it normally allows non-pathogenic or low pathogenic parasites to express their pathogenicity and cause opportunistic infection in hosts. In addition, parasitosis in domestic animals, such as pigs, horses, cattle, sheep, dogs, cats and poultry, is a universal and serious economic problem. That is, parasitic infection of domestic animals causes anemia, malnutrition, weakness, weight loss, and serious damage to the walls of the intestinal tract, tissues and organs, and can result in a decline in feeding efficiency and productivity, leading to a great economic damage. Therefore, new endoparasite control agents such as a parasiticide, an antiprotozoan or the like have always been desired.
SOLUTION TO THE PROBLEM
The present inventors have conducted extensive research to solve the problems described above. As a result, the present inventors have found that a carboxamide derivative represented by the general formula (I) of the present invention, and a salt thereof have a controlling effect against endoparasites, and have then completed the present invention. That is, the present invention relates to the following.
[1] An endoparasite control agent comprising a carboxamide derivative represented by the general formula (I):
3/34
{where A represents a (C 1 -C ₈ ) alkylene group optionally substituted by a halogen atom, an (C 1 -C ₈ ) alkyl group and / or a (C 3 -C 6) cycloalkyl group; an alkylene group (C 1 -C ₈ ) which is optionally substituted by a halogen atom, an alkyl group (CrC ₈ ) and / or a cycloalkyl group (C ₃ C ₈ ) and is modified by incorporating, in the carbon chain, at least least one heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and -N (R) - (where R represents a hydrogen atom, a (C 1 -C ₆ ) alkyl group group, a cyclo (C3-C6), an alkylcarbonyl (C1 -C6) alkoxycarbonyl group or an _(Ci-C6)); an alkenylene group (C ₂ -C ₈ ) optionally substituted by a halogen atom, an alkyl group (C ₁ -C ₆ ) and / or a cycloalkyl group (C 3 -C 6); an alkenylene group (C ₂ -C ₈ ) which is optionally substituted by a halogen atom, an alkyl group (C 1 -C ₆ ) and / or a cycloalkyl group (C ₃ -C ₆ ) and is modified by incorporation, in the chain carbon, of at least one heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO ₂ - and -N (R) - (where R is as defined above); an alkynylene group (C ₂ -C ₈ ) optionally substituted by a halogen atom, an alkyl group (Οι-Οθ) and / or a cycloalkyl group (C3-C6); or an alkynylene group (C ₂ -C ₈ ) which is optionally substituted by a halogen atom, an alkyl group (C 1 -C ₆ ) and / or a cycloalkyl group (C ₃ -C ₆ ) and is modified by incorporation, in the carbon chain, of at least one heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO ₂ - and -N (R) - (where R is as defined above), and in each case, A can form a cyclic structure, where possible,
E represents a hydrogen atom; a (C 1 -C ₆ ) alkyl group; a cycloalkyl group (C ₃ -C ₆ ); alkoxy _(Ci-C6) alkyl (CrC _6); a (C 1 -C ₆ ) alkylcarbonyl group; or an alkoxycarbonyl group _(Ci-C6), each X may be the same or different and represents a halogen atom; a cyan group; a nitro group; a (C 1 -C ₈ ) alkyl group optionally substituted by a halogen atom; an alkoxy group (C 1 -C ₆ ) optionally substituted by a halogen atom; an alkylthio group (C 1 -C ₆ ) optionally substituted by a halogen atom; a (C 1 -C ₆ ) alkylsulfinyl group optionally substituted by an
Í
4/34 halogen; an alkylsulfonyl group (Ο-ι-Οβ) optionally substituted by a halogen atom, m represents an integer from 0 to 5, each Y can be the same or different, and represents a halogen atom; a cyan group; a nitro group; a hydroxyl group; an alkyl group (CrCe) optionally substituted by a halogen atom; an alkenyl group (C2-C ₆ ) optionally substituted by a halogen atom; an alkynyl group (C2-C6) optionally substituted by a halogen atom; an alkoxy group (C 1 -C ₆ ) optionally substituted by a halogen atom; an alkoxy (C1-C6) alkoxy (CfCe) group; an alkenyloxy group (C2-C6) optionally substituted by a halogen atom; an alkynyloxy group (C2-C6) optionally substituted by a halogen atom; an alkylthio group (C1-C6) optionally substituted by a halogen atom; an alkylsulfinyl group (Ο-ι-Οθ) optionally substituted by a halogen atom; a (C1-C6) alkylsulfonyl group optionally substituted by a halogen atom; an alkoxycarbonyl group (C 1 -C ₆ ); an alkoxyimino (CrCe) alkyl (CrC ₃ ) group; a trialkylsilyl group (C3-C3O); alkylsufonylamino one mono- _(Ci-C6) alkyl optionally substituted by a halogen atom; a phenyl group optionally substituted by one or more substituents selected from substituents in group B; a phenoxy group optionally substituted by one or more substituents selected from substituents in group B; a heterocyclic group optionally substituted by one or more substituents selected from substituents in group B; or a heterocycloxy group optionally substituted by one or more substituents selected from group B substituents, the group B substituents are a halogen atom; a cyan group; a nitro group; an alkyl group (Ο ^ Οθ) optionally substituted by a halogen atom; an alkenyl group (C ₂ -Ce) optionally substituted by a halogen atom; an alkynyl group (C ₂ -Ce) optionally substituted by a halogen atom; an alkoxy group (Οι-Οθ) optionally substituted by a halogen atom; alkenyloxy _(C2-C6) alkyl optionally substituted by a halogen atom; an alkynyloxy group (C ₂ -C ₆ ) optionally substituted by a halogen atom; an alkylthio group (C 1 -C ₆ ) optionally substituted by a halogen atom; an optionally (C 1 -C ₆ ) alkylsulfinyl group
5/34 replaced by a halogen atom; an alkylsulfonyl group (C 1 -C ₆ ) optionally substituted by a halogen atom; an alkoxycarbonyl group (Οι-Οθ); and an alkoxyimino (Ο-ι-Οβ) alkyl (C1-C3) alkyl, n represents an integer from 0 to 5, with the proviso that when n is an integer from 2 to 5, two adjacent Y groups can be join to form a (C3-C5) alkylene group; an alkenylene group (C3-C5); an (C2-C4) alkyleneoxy group; or a (C1-C3) alkylenedioxy group optionally substituted by a halogen atom, and
Z represents a nitrogen atom; CH; or CY (where Y is as 10 defined above)}, or a salt thereof as an active ingredient.
[2] The endoparasitic control agent according to 0 [1] above, in which A represents an alkylene group (Ci-Cg) optionally substituted by a halogen atom, an alkyl _(Ci-C6) and / or a cycloalkyl group (C ₃ 15 C ₆ ); an alkylene group or (Ci-Cs) which is optionally substituted by a halogen atom, an alkyl group (CiC ₆₎ θ / or cycloalkyl _(C3-C6) and is modified by incorporation in the carbon chain , of at least one heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and -N (R) - (where R represents a hydrogen atom, an alkyl group (Ci -C ₆ ), a cycloalkyl group (C ₃ -C ₆ ), an alkylcarbonyl group (CiC ₆ ) or an alkoxycarbonyl group (Ci-Ce)).
[3] The endoparasite control agent according to [1] above, where A represents an alkylene group (C 1 -Cs) optionally substituted by an alkyl group (C 1 -C ₆ ) and / or a cycloalkyl group (C ₃ -C ₆ ); -CR ¹ (R ² ) -CR ³ (R ⁴ ) 25 Q- (where R ¹ , R ² , R ³ and R ⁴ can be the same or different from each other, and represent a hydrogen atom, a group (C 1 -C 6) alkyl or a (C 3 -C 6) cycloalkyl group, or R ¹ , R ² , R ³ and R ⁴ can join in any combination to form a (C 3 -C 6) cycloalkane, and Q represents an atom of oxygen, a sulfur atom, -SO-, -SO2- or -N (R) - (where R represents a hydrogen atom, an alkyl group (C 1 -C ₆ ), a cycloalkyl group (C ₃ -C ₆ ), an alkylcarbonyl group (CÁ-Câ) or an alkoxycarbonyl group (C1-C ₆ ))); or -CR ¹ (R ² ) -CR ³ (R ⁴ ) CR ⁵ (R ⁶ ) -Q- (where R ¹ , R ² , R ³ , R ⁴ and Q are as defined above, and R ⁵ and R ⁶ can be the same or different from each other, and represent a hydrogen atom, an alkyl group (Ci-Ce) or a cycloalkyl group (C3-C6), or R ¹ , R ² , R ³ , 35 R ⁴ , R ⁵ and R ⁶ can join in any combination to form a cycloalkane (C _r C ₆ )).
I
6/34 [4] The endoparasite control agent according to [1] above, where A represents an alkylene group (CrCe) optionally substituted by an alkyl group (CrC ₆ ) θ / or a cycloalkyl group (C ₃ -C ₆ ); -CR ¹ (R ² ) -CR ³ (R ⁴ ) Q- (where R ¹ , R ² , R ³ and R ⁴ can be the same or different from each other, and represent a hydrogen atom, an alkyl group (Ci-Ce) or a cycloalkyl group (C3-C6), or R ¹ , R ² , R ³ and R ⁴ can join in any combination to form a cycloalkane (C3-C6), and Q represents an oxygen atom , a sulfur atom, -SO-, -SO2- or -N (R) - (where R represents a hydrogen atom, an alkyl group (Οι-Οθ), a cycloalkyl group (C3-C6), a group alkylcarbonyl (C1-C6) or an alkoxycarbonyl (C1 -C6) group; or -CR ¹ (R ² ) -CR ³ (R ⁴ ) CR ⁵ (R ⁶ ) -Q- (where R ¹ , R ² , R ³ , R ⁴ and Q are as defined above, and R5 and R6 can be the same or different from each other, and represent a hydrogen atom, a (C-C6) alkyl group or a (C3-C6) cycloalkyl group , or R ¹ , R ² , R ³ , R ⁴ , R ⁵ and R ⁶ can join in any combination to form a cycloalkane (C ₃ -C ₆ )),
E represents a hydrogen atom; a (C1-C6) alkyl group; an alkylcarbonyl group (Ο-ι-Οθ); or an alkoxycarbonyl group (C 1 -C ₆ ), each X can be 0 same or different, and represents a halogen atom; an alkyl group (Ο-ι-Οθ) optionally substituted by a halogen atom; an alkoxy group (C4 Ce) optionally substituted by a halogen atom; or an alkylthio group (C 1 -C ₆ ) optionally substituted by a halogen atom, m represents 1 or 2, each Y can be the same or different, and represents a halogen atom; a hydroxyl group; a (C 1 -C ₆ ) alkyl group optionally substituted by a halogen atom; an alkoxy group (Ο-ι-Οβ) optionally substituted by a halogen atom; an alkoxy (C 1 -C ₆ ) alkoxy (C 1 -C ₆ ) group; an alkenyloxy group (C ₂ -C ₆ ) optionally substituted by a halogen atom; a mono alkylsufonylamino group (C1 ₆ ) optionally substituted by a halogen atom; a phenyl group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, a (C 1 -C ₆ ) alkyl group optionally substituted by a halogen atom, and an alkoxy group (C 1 -C) ₆ ) optionally substituted by a halogen atom; a phenoxy group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a group
7/34 nitro, an alkyl group (C _r C ₆ ) optionally substituted by a halogen atom, and an alkoxy group (Ci-Ce) optionally substituted by a halogen atom; a heterocyclic group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, an alkyl group (Οι-Οθ) optionally substituted by a halogen atom, and an alkoxy group (Οι-Οθ) optionally substituted by a halogen atom; or a heterocycloxy group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, an alkyl (Ci-Ce) group optionally substituted by a halogen atom, and an alkoxy group (Ci-Cô ) optionally substituted by a halogen atom, n represents an integer from 0 to 3, with the proviso that when n is 2 or 3, two adjacent Y groups can be joined to form a (C2-C4) alkyleneoxy group or a alkylenedioxy (C1-C3) group optionally substituted by a halogen atom, and
Z represents a nitrogen atom; CH; or CY (where Y is as defined above).
[5] The endoparasitic control agent according to the above [1], wherein A represents alkylene (C1-C5) optionally substituted by an alkyl _(Ci-C6) and / or a cyclo (C ₃ -C ₆ ); -CR ¹ (R ² ) -CR ³ (R ⁴ ) -Q (where R ¹ , R ² , R ³ and R ⁴ can be the same or different from each other, and represent a hydrogen atom, an alkyl group (C1-C6) or a cycloalkyl group (C3-C6), and Q represents an oxygen atom or a sulfur atom); or -CR ¹ (R ² ) -CR ³ (R ⁴ ) -CR ⁵ (R ⁶ ) -Q- (where R ¹ , R ² , R ³ , R ⁴ and Q are as defined above, and R5 and R6 can be the same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group or a (C3-C6) cycloalkyl group),
E represents a hydrogen atom, each X can be the same or different, and represents a halogen atom or a (C1-C6) alkyl group optionally substituted by a halogen atom, m represents 1, each Y can be the same or different, and represents a halogen atom or a (C 1 -C ₆ ) alkyl group optionally substituted by a
I halogen atom, go
8/34 n represents an integer from 1 to 3, and
Z represents a nitrogen atom; CH; or CY (where Y is as defined above).
[6] A method for controlling endoparasites, comprising administering orally or parenterally an effective amount of the endoparasite control agent according to any of the numbers [1] to [5] above to a non-human mammal or a bird.
[7] A method for controlling endoparasites, comprising administering orally or parenterally an effective amount of the endoparasite control agent according to any of the numbers [1] to [5] above to a non-human mammal.
[8] The method according to [7] above in which the non-human mammal is a domestic animal.
ADVANTAGE EFFECTS OF THE INVENTION
The present invention provides a compound useful as an endoparasite control agent which excels in performance when compared to the conventional technique.
DESCRIPTION OF THE MODALITIES
The definitions in general formula (I) representing the carboxamide derivative of the present invention are described below.
The "(C 1 -C ₈ ) alkylene group" refers to a linear (CrC ₈ ) alkylene, for example, a methylene group, an ethylene group, a trimethylene group, a tetramethylene group, a pentamethylene group, a hexamethylene group, a heptamethylene group, an octamethylene group or the like. The "alkylene group (CiC ₈₎ optionally substituted by a halogen atom, an alkyl group (CiC ₆₎ cycloalkyl or (C ₃ -C _6)" each substituent may be attached at any carbon atom in the group alkylene. The "alkylene group (Ci-C ₈₎ which is optionally substituted by a halogen atom, an alkyl _(Ci-C6) or cycloalkyl (C3-C6) and is modified by incorporation in the carbon chain, of at least one heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and -N (R) - ”refers to a group 0 which is the same as the alkylene group ( Optionally substituted linear CrC ₈ ) mentioned above except for having such a hetero atom attached to a terminal carbon atom or inserted between carbon atoms in the alkylene group. Specific examples include an ethyleneoxy group, an ethylene thio group, an ethylene sulfinyl group, an ethylene sulfonyl group, an ethylene amino group, a propyleneoxy group,
9/34 a propylenothio group, a sulfinyl propylene group, a sulfonyl propylene group, an amino propylene group, -CH2-CH2-O-CH2-, -CH2-CH2-S-CH2- and -CH2-CH2-NH-CH2O "(C2-C ₈ ) alkenylene group" refers to a linear (C2-C ₈ ) alkenylene group having one or more double bonds therein, for example, a vinylene group, a propenylene group, a butenylene group, a butadienylene group , a pentenylene group, a pentadienylene group, a hexenylene group, a hexadienylene group, a heptenylene group, a heptadienylene group, an octenylene group, an octadienylene group or the like. In the “alkenylene group (C ₂ 10 C ₈ ) optionally substituted by a halogen atom, an alkyl group (C1C ₆ ) or a cycloalkyl group (C3-C6),” each substituent can be attached to any carbon atom in the alkenylene group . The “alkenylene group (C2-C ₈ ) which is optionally substituted by a halogen atom, an alkyl group (C-iC ₆ ) or a cycloalkyl group (C ₃ -C ₈ ) and is modified by incorporation, in the chain carbon, of at least one heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO ₂ - and -N (R) - ”refers to a group which is the same as the optionally substituted linear (C2-C ₈ ) alkenylene group mentioned above except that it has such a heteroatom attached to a terminal carbon atom or inserted between carbon atoms in the alkenylene group. Specific examples 20 include a vinylene-oxy group, a vinylenothio group, a vinylene sulfinyl group, a sulfonyl vinylene group, an amino vinylene group, a propenylene-oxy group, a propenylenothio group, a propenylene sulfinyl group, a propenylene sulfonyl group, an amino propenylene group, -CH = CH-CH2O-CH2-, CH = CH-CH ₂ -S-CH ₂ - and -CH = CH-CH ₂ -NH-CH ₂ -.
The "alkynylene group (C2-C ₈ )" refers to a linear C2-C ₈ alkynylene group having one or more triple bonds in it, for example, an ethynylene group, a propynylene group, a butynylene group, a butadiene group, a pentynylene group, a pentadinylene group, a hexynylene group, a gruponylene, a heptinylene group, a heptadynylene group, an octinylene group, an octadynylene group or the like. The "alkynylene group _(C2-C8) optionally substituted by a halogen atom, an alkyl _(Ci-C6) cycloalkyl or (C ₃ -C _6)" each substituent may be attached at any carbon atom in the alkylene group. The "alkynylene group (C ₂ -C ₈ )" which is optionally substituted by a halogen atom, an alkyl group (C 1 -C ₆ ) or a cycloalkyl group (C ₃ -C ₈ ) and is modified by incorporation, in the carbon chain, of at least one heteroatom selected from an atom of
10/34 oxygen, a sulfur atom, -SO-, -SO2- and -N (R) - ”refers to a group which is the same as the optionally substituted linear alkylene group (C2-C ₈ ) mentioned above except for having such a hetero atom attached to a terminal carbon atom or inserted between carbon atoms in the alkynylene group. Specific examples include an ethynylene-oxy group, an ethinylenethio group, a sulfinyl ethinylene group, a sulfonyl ethinylene group, an amino ethynylene group, a propynylene-oxy group, a propynylene-thio group, a sulfinyl-propynylene group, a sulfonyl-propynylene group, amino propynylene group, -CeC-CH ₂ -O-CH ₂ -, -CsC-CH ₂ -SCH ₂ - and -C eC-CH ₂ -NH-CH ₂ -.
The “halogen atom” refers to a chlorine atom, a bromine atom, an iodine atom or a fluorine atom. The "(C1-C6) alkyl group" refers to a linear or branched alkyl group of 1 to 6 carbon atoms, for example, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an nbutyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, neopentary group, n-hexyl group or the like.
The "alkyl group (Οι-Οθ) optionally substituted by a halogen atom" refers to a linear or branched alkyl group of 1 to 6 carbon atoms, for example, a methyl group, an ethyl group, an n- propyl, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, a neopentyl group, an n-hexyl group or the like; and also refers to a linear or branched alkyl group of 1 to 6 carbon atoms replaced by one or more halogen atoms which may be the same or different from each other, for example, a trifluoromethyl group, a difluoromethyl group, a perfluoroethyl group, a hexafluoroisopropyl group, a perfluoroisopropyl group, a chloromethyl group, a bromomethyl group, a 1bromoethyl group, a 2,3-dibromopropyl group or the like.
The "alkenyl group (C ₂ -Ce)" optionally substituted by a halogen atom "refers to a linear or branched alkenyl group of 2 to 6 carbon atoms, for example, a vinyl group, a propenyl group, a group butenyl. or the like; and also refers to a linear or branched alkenyl group of 2 to 6 carbon atoms replaced by one or more halogen atoms which can be the same or different from each other, for example, a fluorovinyl group, a difluorovinyl group, a perfluorovinyl group, a 3,3-dichloro-2propenyl group, a 4,4-difluoro-3-butenyl group or the like.
The "alkynyl group (Ο ₂ -Ο ₆ )" optionally substituted by a halogen atom "refers to a linear or branched alkynyl group of 2 to 6 atoms of i,
11/34 carbon, for example, an ethynyl group, a propynyl group, a butynyl group or the like; and also refers to a linear or branched alkynyl group of 2 to 6 carbon atoms replaced by one or more halogen atoms which may be the same or different from each other, for example, a fluoroethynyl group, a perfluoropropinyl group, a 4,4,4-trifluoro-2-butynyl group or the like.
The "alkoxy group (Οι-Οε)" optionally substituted by a halogen atom "refers to a linear or branched alkoxy group of 1 to 6 carbon atoms, for example, a methoxy group, an ethoxy group, a n group -propoxy, an isopropoxy group, an n-butoxy group, a sec-butoxy group, a tert-butoxy group, an n-pentyloxy group, an isopentyloxy group, a neopentyloxy group, a nhexyloxy group or the like; and also refers to a linear or branched alkoxy group of 1 to 6 carbon atoms replaced by one or more halogen atoms which may be the same or different from each other, for example, a trifluoromethoxy group, a difluoromethoxy group, a perfluoroethoxy group, a perfluoroisopropoxy group, a chloromethoxy group, a bromomethoxy group, a 1-bromoethoxy group, a 2,3-dibromopropoxy group or the like.
The "alkoxy group (Ci-Οθ) alkoxy group (Οι-Οθ)" refers to a linear or branched alkoxy group of 1 to 6 carbon atoms having a linear or branched alkoxy group of 1 to 6 carbon atoms as a substituent in a substitutable position, for example, a methoxyethoxy group, an ethoxyethoxy group, a 1-methoxyethoxy group, a 2-methoxyethoxy group, a 1-ethoxyethoxy group, a 2-ethoxyethoxy group or the like.
The "alkoxy group (Οι-Οθ) alkyl (Οι-Οθ)" refers to a linear or branched alkyl group of 1 to 6 carbon atoms having a linear or branched alkoxy group of 1 to 6 carbon atoms as a substituent in a substitutable position, for example, a methoxymethyl group, an ethoxymethyl group, a 1-methoxyethyl group, a 2-methoxyethyl group, a 1-ethoxyethyl group, a 2-ethoxyethyl group or the like.
The "alkenyloxy group (Ο2-Οθ)" optionally substituted by a halogen atom, refers to a linear or branched alkenyloxy group of 2 to 6 carbon atoms, for example, a propenyloxy group, butenyloxy group, pentenyloxy group or the like ; and also refers to a linear or branched alkenyloxy group of 2 to 6 carbon atoms replaced by one or more halogen atoms which may be the same or different from one another, for example, a fluorovinyloxy group, a difluorovinyloxy group, a group
112/34 perfluorovinyloxy, a 3,3-dichloro-2-propenyloxy group, a 4,4-difluoro-3butenyloxy group or the like.
The "alkynyloxy group (C2-C6) optionally substituted by a halogen atom" refers to a linear or branched alkynyloxy group of 2 to 6 carbon atoms, for example, a propynyloxy group, butynyloxy group, a pentynyloxy group or the like ; and also refers to a linear or branched alkynyloxy group of 2 to 6 carbon atoms replaced by one or more halogen atoms which may be the same or different from each other, for example, a fluoroethynyloxy group, a perfluoropropynyloxy group, a group 4,4,4trifluoro-2-butynyloxy or the like.
The "alkylthio group (Οι-Οθ) optionally substituted by a halogen atom" refers to a linear or branched alkylthio group of 1 to 6 carbon atoms, for example, a methylthio group, an ethylthio group, an n- propylthio, an isopropylthio group, an n-butylthio group, a sec-butylthio group, a tert-butylthio group, an n-pentylthio group, an isopentylthio group, an n-hexylthio group or the like; and also refers to a linear or branched alkylthio group of 1 to 6 carbon atoms replaced by one or more halogen atoms which may be the same or different from each other, for example, a trifluoromethylthio group, a difluoromethylthio group, a perfluoroethylthio group, a perfluoroisopropylthio group, a chloromethylthio group, a bromomethylthio group, a 1bromoethylthio group, a 2,3-dibromopropylthio group or the like.
The "(C1-C6) alkylsulfinyl group optionally substituted by a halogen atom" refers to a linear or branched alkylsulfinyl group of 1 to 6 carbon atoms, for example, a methylsulfinyl group, an ethylsulfinyl group, an n- propylsulfinyl, an isopropylsulfinyl group, an n-butylsulfinyl group, a sec-butylsulfinyl group, a tert-butylsulfinyl group, an n-pentylsulfinyl group, an isopentylsulfinyl group, an n-hexylsulfinyl group or the like; and also refers to a linear or branched alkylsulfinyl group of 1 to 6 carbon atoms replaced by one or more halogen atoms which may be the same or different from each other, for example, a trifluoromethylsulfinyl group, a difluoromethylsulfinyl group, a perfluoroethylsulfinyl group, a perfluoroisopropylsulfinyl group, a chloromethylsulfinyl group, a bromomethylsulfinyl group, a 1-bromoethylsulfinyl group, a 2,3dibromopropylsulfinyl group or the like.
The "alkylsulfonyl group (C1- Cê) optionally substituted by a halogen atom" refers to a linear or branched alkylsulfonyl group of 1 to 6 t atoms
J
13/34 carbon, for example, a methylsulfonyl group, an ethylsulfonyl group, an n-propylsulfonyl group, an isopropylsulfonyl group, an n-butylsulfonyl group, a sec-butylsulfonyl group, a tert-butylsulfonyl group, an n-pentylsulfonyl group , an isopentylsulfonyl group, an n-hexylsulfonyl group or the like; and also refers to a linear or branched alkylsulfonyl group of 1 to 6 carbon atoms replaced by one or more halogen atoms which may be the same or different from each other, for example, a trifluoromethylsulfonyl group, a difluoromethylsulfonyl group, a perfluoroisopropylsulfonyl, bromomethylsulfonyl, a dibromopropylsulfonyl or the like.
The "alkylcarbonyl group _(Ci-C6)" refers to a group perfluoroetilsulfonil group, a chloromethylsulfonyl group, 1-bromoetilsulfonil, one of a group group group
2,3 linear or branched alkyl of 1 to 6 carbon atoms attached to a carbonyl group, for example, a methylcarbonyl group, an ethylcarbonyl group, an n-propylcarbonyl group, an isopropylcarbonyl group, an n-butylcarbonyl group, a tert-butylcarbonyl group or the like.
The "alkoxycarbonyl group (C1-C ₆ )" refers to a linear or branched alkoxy group of 1 to 6 carbon atoms attached to a carbonyl group, for example, a methoxycarbonyl group, an ethoxycarbonyl group, an n-propoxycarbonyl group , an isopropoxycarbonyl group, an n-butoxycarbonyl group, a tert-butoxycarbonyl group or the like.
The "alkoxyimino _(Ci-C6) alkyl (C1-C3) alkyl " refers to a straight or branched alkoxy group of 1 to 6 carbon atoms attached to an imino group (C1-C3) alkyl, for example, a methyl methoxyimino group, methyl ethoxyimino group, n-propoxyimino methyl group, isopropoxyimino ethyl group or the like.
The "trialkylsilyl group (C3-C3O)" refers to a linear or branched alkylsilyl group of 3 to 30 carbon atoms in total, for example, a trimethylsilyl group, a triethylsilyl group or the like.
The "mono alkylsufonylamino group (C1-C ₆ ) optionally substituted by a halogen atom" refers to a linear or branched mono alkylsufonylamino group of 1 to 6 carbon atoms, for example, a methylsulfonylamino group, an ethylsulfonylamino group, a group isopropylsulfonylamino or the like; and also refers to a linear or branched monoalkylsufonylamino group of 1 to 6 carbon atoms replaced by one or more halogen atoms which may be the same or different from one another, for example, a trifluoromethylsulfonylamino or similar group.
14/34
The "cycloalkane (C ₃ -C ₆ )" that R ¹ , R ² , R ³ and R ⁴ can join in any combination to form and the "cycloalkane (C3-C6)" that R ¹ , R ² , R ³ , R ⁴ , R ⁵ and R ⁶ can come together in any combination to form, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane or the like.
Examples of the "(C2-C4) alkyleneoxy group" include -CH2-CH2-O-, -CH ₂ C (CH ₃ ) 2-O-, -CH2-CH2-CH2-O- and -CH2-CH2-CH2- CH2-O-.
The "alkylenedioxy group _(Ci-C3) alkyl optionally substituted by a halogen atom" refers to an alkylenedioxy group of 1 to 3 carbon atoms, for example, -O-CH2-O-, -O-CH2-CH2 -O-, -O-CH2-CH2-CH2-O- or the like; and 10 also refers to an alkylenedioxy group of 1 to 3 carbon atoms replaced by one or more halogen atoms which can be the same or different from each other, for example, -O-CF2-O-, -O -CF2-CF2-O-, -O-CCI2-O or similar.
The "heterocyclic group" refers to a group of 5 or 6 members aromatic monocyclic 15, or a group of 3 or 6 members non-aromatic monocyclic containing, as ring atoms, one (s) atom (s) of carbon and 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom; and also refers to a condensed heterocyclic group formed by condensing such a monocyclic or non-aromatic heterocyclic aromatic with a benzene ring or by condensing such monocyclic or non-aromatic heterocyclic aromatics (the heterocyclics may differ from each other).
Examples of the "aromatic heterocyclic group" include monocyclic aromatic heterocyclic groups, such as furyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 25 pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, toxyazolyl, triazole, triazinyl; and aromatic condensed heterocyclic groups, such as quinolyl, isoquinolyl, quinazolyl, quinoxalyl, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzimidazolyl, benzotriazolyl, indolyl, indazolyl, pyrrolazole, pyrrolopyrazole
Examples of the "non-aromatic heterocyclic group" include monocyclic non-aromatic heterocyclic groups, such as oxiranyl, thiiranyl, aziridinyl, oxetanyl, tietanyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, 35thiomorpholinyl, piperazinyl, thiazolidinyl, oxiperazinyl, thiazolidine thiazolinyl, imidazolinyl, dioxolyl, dioxolanyl,
15/34 dihydrooxadiazolyl, 2-oxo-1, 3 - oxazolidin-5-yl, pyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl 1,1-dioxide tetrahydrofuryl, tetrahydrofuryl, dioxanyl , pyrazolidinyl, pyrazolinyl, tetrahydropyrimidinyl, dihydrotriazolyl and tetrahydrotriazolyl; and non-aromatic condensed heterocyclic groups, such as dihydroindolyl, dihydroisoindolyl, dihydrobenzofuranyl, dihydrobenzodioxinyl, dihydrobenzodioxepinyl, tetrahydrobenzofuranyl, chromenyl, dihydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinyl, dihydroquinolinyl, dihydroquinolinyl, dihydroquinolinyl, dihydroquinoline.
Examples of a salt of the carboxamide derivative represented by the general formula (I) of the present invention include salts of inorganic acid, such as hydrochlorides, sulfates, nitrates and phosphates; organic acid salts, such as acetates, fumarates, maleates, oxalates, methanesulfonates, benzenesulfonates and P-toluenesulfonates; and salts with an inorganic or organic base such as a sodium ion, a calcium ion and a trimethylammonium ion.
As the carboxamide derivative of the present invention, a compound of the general formula (I) is preferred wherein A represents an alkylene group (C 1 -Cs) optionally substituted by an alkyl group (C 1 -C) and / or a cycloalkyl group (C 3) -C6); -CR ¹ (R ² ) -CR ³ (R ⁴ ) -Q- (where R ¹ , R ² , R ³ and R ⁴ can be the same or different from each other, and represent a hydrogen atom, a group 20 alkyl _(Ci-C6) cycloalkyl or _(C3-C6), or R ^1, R ^2, R ³ and R ⁴ can join in any combination to form a cycloalkane _(C3-C6), and Q represents an oxygen atom, a sulfur atom, -SO-, -SO2- or -N (R) - (where R represents a hydrogen atom, an alkyl group (C 1 -C ₆ ), a cycloalkyl group ( C ₃ -C _6), an alkylcarbonyl group _(Ci-C6) alkoxycarbonyl group or an _(Ci-C6))); or 25 CR ¹ (R ² ) -CR ³ (R ⁴ ) -CR ⁵ (R ⁶ ) -Q- (where R ¹ , R ² , R ³ , R ⁴ and Q are as defined above, and R5 and R6 they may be the same or different from each other, and represent a hydrogen atom, an alkyl group (C 1 -C ₆ ) or a cycloalkyl group (C ₃ -C ₆ ), or R ¹ , R ² , R ³ , R ⁴ , R ⁵ and R ⁶ can join in any combination to form a cycloalkane (C3-C6)),
E represents a hydrogen atom; a (C 1 -C ₆ ) alkyl group; an alkylcarbonyl group (Ci-Ce); or an alkoxycarbonyl group _(Ci-C6), each X may be the same or different and represents a halogen atom; an alkyl group (C4 -Ce) optionally substituted by a halogen atom; an alkoxy group (Ο ^ Οθ) optionally substituted by a halogen atom; or an alkylthio group (C 1 -C ₆ ) optionally substituted by a halogen atom, <
16/34 m represents 1 or 2, each Y can be the same or different, and represents a halogen atom; a hydroxyl group; an alkyl group (Ο ^ Οθ) optionally substituted by a halogen atom; an alkoxy group (Οι-Οβ) optionally substituted by a halogen atom; an alkoxy (C 1 -C ₆ ) alkoxy (C 1 -C) group; an alkenyloxy group (C2-C6) optionally substituted by a halogen atom; a monoalkylsufonylamino group (C1-C6) optionally substituted by a halogen atom; a phenyl group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group optionally substituted by a halogen atom, and an alkoxy group (Ci-C ₆ ) optionally substituted by a halogen atom; a phenoxy group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group optionally substituted by a halogen atom, and an (C1-C6) alkoxy group optionally substituted by a halogen atom; a heterocyclic group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group optionally substituted by a halogen atom, and an alkoxy group (Ci-Cô) optionally substituted by a halogen atom; or a heterocycloxy group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, an alkyl group (Οι-Οθ) optionally substituted by a halogen atom, and an alkoxy group (Ci-C ₆ ) optionally substituted by a halogen atom, n represents an integer from 0 to 3, with the proviso that when n is 2 or 3, two adjacent Y groups can be joined to form an alkyleneoxy group (C ₂ -C ₄ ) or a (C1-C3) alkylenedioxy group optionally substituted by a halogen atom, and
Z represents a nitrogen atom; CH; or CY (where Y is as defined above).
More preferred is a compound of formula (I) wherein A represents alkylene (C1-C5) optionally substituted by an alkyl _(Ci-C6) and / or a cyclo (C ₃ -C _6); -CR ¹ (R ² ) -CR ³ (R ⁴ ) -Q- (where R1, R2, R3 and R4 can be the same or different from each other, and <
17/34 represent a hydrogen atom, an alkyl group (C 1 -C ₆ ) or a cycloalkyl group (C 3 -C 6), and Q represents an oxygen atom or a sulfur atom); or -CR ¹ (R ² ) -CR ³ (R ⁴ ) -CR ⁵ (R ⁶ ) -Q- (where R ¹ , R ² , R ³ , R ⁴ and Q are as defined above, and R5 and R6 can be the same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group or a (C3-C6) cycloalkyl group),
E represents a hydrogen atom, each X can be the same or different, and represents a halogen atom or an alkyl group (CrC ₆ ) optionally substituted by a halogen atom, m represents 1, each Y can be the same or different , and represents a halogen atom or a (C- | -C ₆ ) alkyl group optionally substituted by a halogen atom, n represents an integer from 1 to 3, and
Z represents a nitrogen atom; CH; or CY (where Y is as defined above).
The compound represented by the general formula (I) of the present invention is a known compound, and can be produced by the production method described in JP-A 01-151546, WO 2007/060162, JP-A 53-9739, WO 2007/108483 , WO 2008/101975, WO 2008/101976, WO 2008/003745, WO 2008/003746, WO 2009/012998, WO 2009/127718 or WO 2010/106071, The method described in ShinJikken Kagaku Kouza 14 (Maruzen, 20 December , 1977), a modified method of those preceding it, or the like.
Representative examples of the carboxamide derivative represented by the general formula (I) of the present invention are shown in Table 1, but the present invention is not limited to them. In Table 1, "Me" represents a methyl group, "Et" represents an ethyl group, "Pr" represents a propyl group, "Bu" represents a butyl group, "Ph" represents a phenyl group, "c-" represents a cycle , "I" stands for iso, "t-" stands for tertiary, and physical property refers to a melting point (° C).
Regarding the compounds shown with the note “Paste” in the column “Physical property” in Table 1, their HNMR spectrum ¹ data are shown in Table 5. Q1 to Q7 represent the following structures.
18/34
OMe N = <
Q ,;
OMe
Table 1
Number ofCompound (X) m R ¹ R ² R ³ R ⁴ (Y) n Physical property 1-1 2-CF ₃ H H H H 2-CI 104.9-105.7 1-2 2-CF ₃ H H H H 3-CF ₃ 63-65 1-3 2-CF ₃ H H H H 4-CI 116.6-117.6 1-4 2-CF ₃ H H Me H 4-CI 89 1-5 2-CF ₃ H H Me Me 4-CI 91-92 1-6 2-CF ₃ H H Et H 4-CI Necklace 1-7 2-CF ₃ H H Me Et 4-CI Necklace 1-8 2-CF ₃ H H Et Et 4-CI Necklace 1-9 2-CF ₃ H H i-Bu H 4-CI Necklace 1-10 2-I H H Me H 4-CI 119 1-11 2-I H H Me Me 4-CI 121-122 1-12 2-I H H Et H 4-CI 103 1-13 2-I H H Me Et 4-CI Necklace 1-14 2-I H H Et Et 4-CI Necklace 1-15 2-I H H i-Bu H 4-CI 86-91 1-16 2-CF ₃ H H H H 2,4-CI ₂ 104.2-105.2
19/34
1-17 2-CF ₃ H H H H 2,3-Cb 135-136 1-18 2-I H H H H 2,3-CI ₂ 145-146 1-19 2-CF ₃ H H H H 2,6-CI ₂ 148.4-149.4 1-20 2-CF3 H H H H 3,4-CI ₂ 95-96.8 1-21 2-I H H H H 3,4-CI ₂ 107.2-109.2 1-22 2-CF3 H H H H 2-CI-4-F 81.5-82.8 1-23 2-CF3 H H H H 2-Me-4-CI 97-98 1-24 2-I H H H H 2-Me-4-CI 121-122.7 1-25 2-CF3 H H H H 2,5-CI ₂ 89.8-90.9 1-26 2-CF3 H H H H 2.4- (CF ₃ ) ₂ 112.9-113.7 1-27 2-CF3 H H H H 2,4-Me ₂ 75.1-77.2 1-28 2-CF3 H H H H 2.5-Me ₂ 94-95 1-29 2-I H H H H 2.5-Me ₂ 115-116 1-30 2-CF3 H H H H 2-CI-5-CF3 95.7-96.9
Table 1 (Continued)
Number ofCompound (X) m R ¹ R ² R ³ R ⁴ (Y) n Physical property 1-31 2-I H H H H 2-CI-5-CF3 122-123 1-32 2-CF3 Me H H H 2,4-CI ₂ 142 1-33 2-I Me H H H 2,4-CI ₂ 161-162 1-34 2-CF3 H H CH ₂ CH ₂ 2,4-CI ₂ 108-112 1-35 2-I H H ch ₂ ch ₂ 2,4-CI ₂ 101-103 1-36 2-F H H ch ₂ ch ₂ 2,4-CI ₂ 99-101 1-37 2-CF3 Me H ch ₂ ch ₂ 2,4-CI ₂ 107-110 1-38 2-I Me H ch ₂ ch ₂ 2,4-CI ₂ 50-51 1-39 2-CF3 H H H H 2-F-4-CF3 94-97 1-40 2-I H H H H 2-F-4-CF3 118 1-41 2schf ₂ H H H H 2,4-CI ₂ 103 1-42 2-I H H H H 2,4-CI ₂ 125-126 1-43 2-Br H H H H 2,4-CI ₂ 127-128 1-44 2-CI H H H H 2,4-CI ₂ 124-126 1-45 2-Me H H H H 2,4-CI ₂ 136-138 1-46 2-F H H H H 2,4-CI ₂ 78 1-47 2,6-F ₂ H H H H 2,4-CI ₂ 75-76
20/34
1-48 2- ocf ₃ H H H H 2,4-CI ₂ 88-90 1-49 2-CF ₃ H H H H 4-Ph (4'-OCF ₃ ) 64-65 1-50 2-CF ₃ H H H H 2-F-4-Ph (4'-OCF ₃ ) 146-148 1-51 2-CF ₃ H H H H 2-CI-4-CF ₃ 102-103 1-52 2-CF ₃ H H H H 2-F-4-CI 101-102 1-53 2-CF ₃ H H H H 2-Me-4-CF (CF ₃ ) ₂ Necklace 1-54 2-I H H H H 2-Me-4-CF (CF ₃ ) ₂ 98-100 1-55 2-CF ₃ H H H H 2,4-F ₂ 94.4-95.8 1-56 2-CF ₃ H H H H 2-CI-4-OCHF ₂ 1-57 2-CF ₃ H H H H 2-CI-4-Qi 135.7-137.2 1-58 2-CF ₃ H H H H 2-CI-4-Q ₂ 137.8-138.8 1-59 2-CF ₃ H H H H 2-CI-4-OPh Necklace 1-60 2-CF ₃ H H H H 2-CI-4-OPh (4'-CF ₃ ) 109.6-111.5
Table 1 (Continued ^
Compound Number Q9m R ¹ R ² R ³ R ⁴ (Y) n Physical property 1-61 2-CF ₃ H H H H 2,4,5-CI ₃ 130-131.6 1-62 2-CF ₃ H H H H 2,4,5-F ₃ 1-63 2-CF ₃ Me H H H 2-CI-4-CF ₃ 144.5-145.5 1-64 2-CF ₃ Me H H H 2,4-F ₂ 121.5-124.5 1-65 2-CF ₃ Me H H H 2-F-4-CI 140.7-142.3 1-66 2-CF ₃ Me H H H 2-CI-4-OH 169.2-171.6 1-67 2-CF ₃ Me H H H 2-CI-4-OCHF ₂ 1-68 2-CF ₃ Me H H H 2-CI-4-OCH ₂ OCH ₃ 109.2-112.9 1-69 2-CF ₃ Me H H H 2-CI-4-Qi 159.5-160.8 1-70 2-CF ₃ Me H H H 2-CI-4-Q ₂ 1-71 2-CF ₃ Me H H H 2-CI-4-Q ₃ 123.9-125.4 1-72 2-CF ₃ Me H H H 2-CI-4-Q41-73 2-CF ₃ Me H H H 2-CI-4-Q5> 1-74 2-CF ₃ Me H H H 2-CI-4-Q ₆ 1-75 2-CF ₃ Me H H H 2-CI-4-Q71-76 2-CF ₃ Me H H H 2-CI-4-OPh 118.3-119.8 1-77 2-CF ₃ Me H H H 2-CI-4-OPh (4'-CF ₃ )
21/34
1-78 2-CF ₃ Me H H H 2-CI-4-OPh (4’-CI)1-79 2-CF3 Me H H H 2,4,5-F ₃ 146.9-148.7 1-80 2-CF3 Me H H H 2,4,5-CI ₃ 1-81 2-CF3 Me H H H 3,4-CI ₂ 133 1-82 2-I Me H H H 3,4-CI ₂ 143 1-83 2-CF3 Me H H H 3-OCF ₂ O-41-84 2-CF3 Me H H H 3-OCF ₂ CF ₂ O-41-85 2-CF3 Me H H H 2-CI, 4-OCF ₂ O-51-86 2-CF3 Me H H H 2-F, 4-OCF ₂ O-51-87 2-CF3 Me Me H H 2,4-CI ₂ 121 1-88 2-CF3 Me Me H H 3,4-CI ₂ 1-89 2-CF3 Me Me H H 2,4-F ₂ 1-90 2-CF3 Me Me H H 3,4-F ₂
Table 1 (Continuation /
Compound Number (X) m R ¹ R ² R ³ R ⁴ (Y) n Physical property 1-91 2-CF3 CH ₂ CH ₂ H H 2,4-CI ₂ 1-92 2-CF3 ch ₂ ch ₂ H H 2-CI-4-CF31-93 2-CF3 ch ₂ ch ₂ H H 2-F-4-CF31-94 2-CF3 H H H H 2.5-F ₂ -4-CI 95.4-96.2 1-95 2-CF3 Me H H H 2.5-F ₂ -4-CI1-96 2-CF3 H H H H 2-CI-4,5-F ₂ 1-97 2-CF3 Me H H H 2-CI-4,5-F ₂ 1-98 2-CFs H H H H 2-F-4,5-CI ₂ 1-99 2-CF3 Me H H H 2-F-4,5-CI ₂ 1-100 2-CF3 H H H H 2,4-CI ₂ -5-F 98.7-99 1-101 2-CF3 Me H H H 2,4-CI ₂ -5-F1-102 2-CF3 H H H H 2-CI-4-SMe 74.1-76.3 1-103 2-CF3 Me H H H 2-CI-4-SMe 125.4-128.4 1-104 2-CFs H H H H 2-CI-4-SOMe 128.9-129.6 1-105 2-CF3 H H H H 2-CI-4-SO ₂ Me 135.4-137.1 1-106 2-CF3 Me H H H 2-Br-4-CI 143 1-107 2-CF3 H H H H 2-Br-4-F 106.4 1-108 2-CF3 H H H H 3-OCF ₂ O-4 126
22/34
1-109 2,6-F ₂ H H H H 2-CI-4-Qi 134.6-136.7 1-110 2-CF ₃ H H H H 2,6-CI ₂ -4-CF ₃ 153.2-154.2 1-111 2-CF3 H H H H H 98-99 1-112 2-CF3 H H Me Me 2,4-CI ₂ Necklace
Table 2
Compound Number (X) m R ¹ R ² (Y) n Physical property 2-1 2-CF3 H H 4-t-Bu 104-105 2-2 2-CFs H H 3-CF ₃ SO ₂ NH 120-121 2-3 2-CF3 Me Me H 122-124 2-4 2-CFs c-Pr H 4-CI 127-130 2-5 2-CFs H H 3-Me-4-Ph (4'-OCF ₃ ) 122-123 2-6 2-CFs H H 2,4-CI ₂ 143-144 2-7 2-CF3 Me H 2,4-CI ₂ 148-149 2-8 2-CFs Me H 4-CI 128-129 2-9 4-t-Bu H H 4-t-Bu 137-138 2-10 2,6-F ₂ H H 4-t-Bu 56-58
Table 3
Number ofCompound (X) m Y ¹ Y ² Physical Property Value 3-1 2-CI Cl cf ₃ 95-96 3-2 2-Br Cl cf ₃ 104-106 3-3 2-I Cl cf ₃ 128-129 3-4 2-CH3 Cl cf ₃ 107-109
23/34
3-5 2-CF ₃ H H 112-113 3-6 2-CF3 H cf ₃ 91-92 3-7 2-CF3 Cl cf ₃ 106-111 3-8 2-SCH3 Cl cf ₃ 89-90 3-9 4-CF3 Cl cf ₃ 151-152 3-10 2,6-F Cl cf ₃ 98-99 3-11 2,6-CI Cl cf ₃ 110-111
Table 4
Compound Number (X) m R ¹ R ² R ³ R ⁴ Q (Y) n Physical property 4-1 2-CFs H H H H O 2,4-Ch 95.5-96.4 4-2 2-CFs Me H H H O 2,4-Ch 110.8-112.4 4-3 2-CFs H H H H O 2,4-Me ₂ 101.5-103.9 4-4 2-CF3 H H H H CH ₂ O 2,4-Ch 92.6-95.3 4-5 2-CFs H H H H CH ₂ S 2,4-Μθ2 98.4-99.9 4-6 2-CFs H H H H ch ₂ s 2,4-Ch 121.6-122.2 4-7 2-CFs H H H H ch ₂ 2,4-Ch 115.3-116.9 4-8 2-CF3 Me H H H ch ₂ 2,4-Ch 130.4-131.4 4-9 2-CFs H H H Me O 2,4-Ch4-10 2-CF3 H H H H s 2,4-Ch
Table 5
Compound Number ¹ H-NMR [CDCI ₃ / TMS, δ value (ppm)] 1-6 7.65 (dd, 1H), 7.51 (m, 2H), 7.32 (dd, 1H), 7.30 (d, 2H), 7.14 (d, 2H), 5.58 (br, 1H), 3.92 (m, 1H), 3.38 (m, 1H), 2.80 (m, 1H), 1.79 (m, 1H), 1.60 (m, 1H), 0.83 (t, 3H) 1-7 7.65 (d, 1H), 7.51 (m, 2H), 7.25-7.36 (m, 5H), 5.40 (br, 1H),3.77 (dd, 1H), 3.59 (dd, 1H), 1.80 (m, 1H), 1.66 (m, 1H),1.37 (s, 3H), 0.74 (t, 3H)
24/34
1-8 7.65 (dd, 1H), 7.51 (m, 2H), 7.26-7.37 (m, 5H), 5.31 (br, 1H),3.74 (d, 2H), 1.75 (m, 4H), 0.79 (t, 6H) 1-9 7.65 (dd, 1H), 7.51 (m, 2H), 7.32 (dd, 1H), 7.29 (d, 2H), 7.15 (d, 2H), 5.56 (br, 1H), 3.87 (m, 1H), 3.33 (m, 1H), 2.98 (m, 1H), 1.53 (m, 2H), 1.40 (m, 1H), 0.87 (t, 6H) 1-13 7.81 (dd, 1H), 7.27-7.34 (m, 5H), 7.22 (dd, 1H), 7.05 (dt, 1H), 5.43 (br, 1H), 3.76 (dd, 1H), 3.61 (dd, 1H) , 1.83 (m, 1H),1.68 (m, 1H), 1.41 (s, 3H), 0.75 (t, 3H) 1-14 7.81 (dd, 1H), 7.30-7.35 (m, 5H), 7.22 (dd, 1H), 7.06 (dt, 1H),5.34 (br, 1H), 3.75 (d, 2H), 1.78 (m, 4H), 0.81 (t, 6H) 1-53 7.70 (d, 1H), 7.58 (t, 1H), 7.53 (t, 1H), 7.46 (d, 1H),7.40 (s, 1H), 7.39 (d, 1H), 7.30 (d, 1H), 5.86 (br, 1H),3.71 (dd, 2H), 3.00 (t, 2H), 2.44 (s, 3H) 1-59 7.69 (d, 1H), 7.47-7.60 (m, 3H), 7.36 (t, 2H), 7.24 (d, 1H), 7.15 (t, 1H), 7.00-7.03 (m, 3H), 6.88 (dd, 1H), 5.85 (br, 1H), 3.73 (q, 2H), 3.05 (t, 2H)
The endoparasite control agent of the present invention has an excellent anti-endoparasite effect, and has an appropriate control effect against endoparasites. The animal for which the endoparasite control agent of the present invention can be used is a human and an animal of non-human or avian mammalian species. Exemplary members of the non-human mammal species include domestic animals, such as pigs, horses, cattle, sheep, goats, rabbits, camels, water buffalo, deer, mink and chinchillas; pets, such as dogs, cats, small birds and monkeys; and experimental animals, such as rats, mice, golden hamsters and guinea pigs. Exemplary members of avian species include domestic birds, such as chickens, ducks, aigamo ducks (crossings of wild and domestic ducks), quails, domestic ducks, geese and turkeys.
Human endoparasites against which the endoparasite control agent of the present invention is effective are roughly classified into 15 protozoa and helminths. Examples of protozoa include, but are not limited to, Rhizopoda, such as Entamoeba histolytica-, Mastigophora, such as Leishmania, Trypanosoma and Trichomonas; Sporozoea, such as Plasmodium and
25/34
Toxoplasma ', and Ciliophora, such as Balantidium coli. Examples of helminths include, but are not limited to, Nematoda, such as Ascarís lumbricoides, Anisakis, Toxocara canis, Trichostrongylus spp., Enterobius vermicularís, hookworms (for example, Ancylostoma duodenale, Necator americanus, 5 Ancylostoma braziliense, etc.), Angios spp., Gnathostoma spp., filarial worms (filaria, Wucherería bancrofti, Brugia malayi, etc.), Onchocerca volvulus, Dracunculus medinensis, Trichinella spiralis and Strongyloides stercoralis', Acanthocephala, such as Macracushirhynhynhyn Gordiacea, such as Gordioidea; Hirudinea, such as Hirudo nipponia ', Trematoda, such as 10 Schistosoma japonicum, Schistosoma mansoni, Schistosoma haematobium,
Clonorchis sinensis, Heterophyes heterophyes, Fasciola spp. and Paragonimus spp .; and Cestoda, such as Diphyllobothrium latum, Sparganum mansoni, Sparganum proliferum, Diplogonoporus grandis, Taeniidae (e.g., Taeniarhynchus saginatus, Taenia solium, Echinococcus, etc.), Hymenolepis spp., Dipylidium 15 caninum, Meseatusides. and Nybelinia surmenicola.
Endoparasites of non-human mammals or birds against which the endoparasite control agent of the present invention is effective are roughly classified into protozoa and helminths. Examples of protozoa include, but are not limited to, Apicomplexa, such as Coccidia 20 (for example, Eimeria, Isospora, Toxoplasma, Neospora, Sarcocystis, Besnoitia, Hammondia, Cryptosporidium, Caryospora, etc.), Haemosporina (for example, Leucocytozo Plasmodium, etc.), Piroplasma (for example, Theileria, Anaplasma, Eperythrozoon, Haemobartonella, Ehrlichia, etc.), and others (for example, Hepatozoon, Haemogregarina, etc.); Microspora, such as 25 Encephalitozoon and Nosema; Mastigophora, such as Trypanosomatina (for example, Trypanosoma, Leishmania, etc.), Trichomonadida (for example, Chilomastix, Trichomonas, Monocercomonas, Histomonas, etc.), and Diplomonadida (for example, Hexamite, Giardia, etc.); Sarcodina, such as Amoebida (for example, Entamoeba histolytica (Entamoeba) etc.); and Ciliophora, such as 30 Balantidium coli (Balantidium), Buxtonella and Entodinium.
Examples of helminths include, but are not limited to, Nematoda, such as Ascaridida (for example, Ascarís suum (Ascarís), Toxocara canis and Toxocara cati (Toxocara), Toxascaris leonina (Toxascaris), Parascaris equorum (Parascaris), Ascaridia galli ( Ascaridia), Heterakis gallinarum (Heterakis), Anisakis, 35 etc.), Oxyurida (for example, Oxyuris equi (Oxyuris), Passalurus ambiguus (Passalurus), etc.), Strongylida (for example, Strongylus vulgaris (Strongylus),
26/34
Haemonchus contortus (Haemonchus), Ostertagia ostertagi (Ostertagia), Trichostrongylus colubriformis (Trichostrongylus), Cooperia punctata (Cooperia), Nematodirus filicollis (Nematodirus), Hyostrongylus rubidus (Hyostrongbertomomum (O), Radius) caninum (Ancylostoma), Uncinaria stenocephala (Uncinaria), Necator americanus (Necator), Bunostomum phlebotomum (Bunostomum), Dictyocaulus viviparus (Dictyocaulus), Metastrongylus elongatus (Metastrongylus Ausculusylusylusylusylistrusylusylistrusylusylusylostratus) Angiostrongylus), Syngamus trachea (Syngamus), 10 Stephanurus dentatus (Stephanurus), etc.), Rhabditida (e.g.
Strongyloides stercoralis (Strongyloides), Micronema, etc.), Spirurida (for example, Thelazia rhodesi (Thelazia), Oxyspirura mansoni (Oxyspirura), Spirocerca lupi (Spirocerca), Gongylonema pulchrum (Gongylonema), Draschiama megas (Draschiachia megas) Habronema), Ascarops 15 strongylina (Ascarops), Physaloptera praeputialis (Physaloptera), Gnathostoma spinigerum (Gnathostoma), etc.), Filariida (for example, Dirofilaria immitis (Dirofilaria), Setaria equina (Setaria), Dipetalonema, Paraipilaria multipilaria) , Onchocerca cervicalis (Onchocerca), etc.), and Enoplida (for example, Parafilaria bovicola (Parafilaria), Stephanofilaria okinawaensis (Stephanofilaria), 20 Trichuris vulpis (Trichuris), Capillaría bovis (Capillaría), Trichosomoides crassicais (Trichosomo) (Trichinella), Dioctophyma renale (Dioctophyma), etc.); Trematodes, such as Fasciolata (for example, Fasciola hepatica (Fasciola), Fasciolopsis buski (Fasciolopsis), etc.), Paramphistomatidae (for example, Homalogaster paloniae (Homalogaster), etc.), 25 Dicrocoelata (for example, Eurytrema pancreaticum (Eurytrema ), Dicrocoelium dendriticum (Dicrocoelium), etc.), Diplostomata (for example, Pharyngostomum cordatum (Pharyngostomum), Alaria, etc.), Echinostomata (for example, Echinostoma hortense (Echinostoma), Echinochasmus, etc.), Troglotmato, etc. , pulmonary worms (Paragonimus), Nanophyetus salmincola 30 (Nanophyetus), etc.), Opisthorchiida (for example, Clonorchis sinensis (Clonorchis) etc.), Heterophyida (for example, Heterophyes heterophyes (Heterophyes), Metagonimus yokogawai (Metagonimus), etc. .), Plagiorchiida (for example, Prosthogonimus ovatus (Prosthogonimus) etc.), and Schistosomatidae (for example, Schistosoma japonicum (Schistosoma) etc.); Cestoda, such as 35 Pseudophylidea (for example, Diphyllobothrium nihonkaiense (Diphyllobothrium),
Spirometra erinacei (Spirometra), etc.), and Cyclophyllidea (for example,
27/34 '® ·
Anoplocephala perfoliata (Anoplocephala), Paranoplocephala mamillana (Paranoplocephala), Moniezia benedeni (Moniezia), Dipylidium caninum (Dipylidium), Mesocestoides lineatus (Mesocestoides), Taenia pisiformis and Taenia hydatigisisigigera (Taenia hydatigera) ), Echinococcus granulosus (Echinococcus), Echinococcus multilocularís (Echinococcus), Taenia solium (Taenia), Taeniarhynchus saginatus (Taeniarhynchus), Hymenolepis diminuta (Hymenolepis), Vampirolepisisillamisine (tam) etc.); Acanthocephala, such as Macracanthorhynchus 10 hirudinaceus (Macracanthorhynchus) and Moniliformis moniliformis (Moniliformis);
Linguatulida, such as Linguatula serrata (Linguatula); and several other parasites.
In different designations, examples of helminths include, but are not limited to, Nematoda, such as Enoplida (for example, Trichuris spp., Capillaría spp., Trichomosoides spp., Trichinella spp., Etc.), Rhabditia (for example, Micronema spp., Strongyloides spp., Etc.), Strongylida (e.g., Strongylus spp., Triodontophorus spp., Oesophagodontus spp., Trichonema spp., Gyalocephalus spp., Cylindropharynx spp., Poteriostomum spp., Cycloc. spp., Oesophagostomum spp., Chabertia spp., Stephanurus spp., Ancylostoma spp., Uncinaria spp., 20 Globocephalus spp., Syngamus spp., Cyathostoma spp., Metastrongylus spp., Dictyocaulus ., Protostrongylus spp., Neostrongylus spp., Cystocaulus spp., Pneumostrongylus spp., Spicocaulus spp., Elaphostrongylus spp., Parelaphostrongylus spp., Parenosus spp., Angacostrongylus spp. Parafilaroides spp., 25 Trichostrongylus s pp., Haemonchus spp., Ostertagia spp., Marshallagia spp., Cooperia spp., Nematodirus spp., Hyostrongylus spp., Obeliscoides spp., Amidostomum spp., Ollulanus spp., etc.),
Oxyurida (for example, Oxyuris spp., Enterobius spp., Passaturus spp., Syphacia spp., Aspiculuris spp., Heterakis spp., Etc.), Ascaridia (for example, 30 Ascaris spp., Toxascaris spp., Toxocara spp. , Parascaris spp., Anisakis spp., Ascaridia spp., Etc.), Spirurida (e.g., Gnathostoma spp., Physaloptera spp., Thelazia spp., Gongylonema spp., Habronema spp., Parabronema spp., Draschia spp., Dracunculus spp., Etc.), and Filariida (for example, Stephanofilaria spp., Parafilaria spp., Setaria spp., Loa spp., Dirofilaria spp., Litomosoides spp., 35 Brugia spp., Wuchereria spp., Onchocerca spp. , etc.);
t ώ
28/34
Acanthocephala (for example, Filicollis spp., Moniliformis spp., Macracanthorhynchus spp., Prosthenorchis spp., Etc.); Trematoda including subclasses, such as Monogenea (for example, Gyrodactylus spp., Dactylogyrus spp., Polystoma spp., Etc.) and Digenea (for example, Diplostomum spp., 5 Posthodiplostomum spp., Schistosoma spp., Trichobilharzia spp., Ornithbilhar spp., Austrobilharzia spp., Gigantobilharzia spp., Leucochloridium spp., Brachylaima spp., Echinostoma spp., Echinoparyphium spp., Echinochasmus spp., Hypoderaeum spp., Fasciola spp., Fasciolid spp. , Typhlocoelum spp .., Paramphistomum spp., Calicophoron spp., 10 Cotylophoron spp., Gigantoctyle spp .., Fischoederius spp., Gastrothylacus spp., Notocotylus spp., Catatropis spp., Plagiorchis spp .., Prosthogonimus spp., Eurytema spp., Troglotrema spp., Paragonimus spp., Collyríclum spp., Nanophyetus spp., Opisthorchis spp., Clonorchis spp., Metorchis spp., Heterophyes spp., Metagonimus spp., etc.);
Cestoda, such as Pseudophyllidea (for example, Diphyllobothríum spp.,
Spirometra spp., Schistocephalus spp., Ligula spp., Bothridium spp., Diplogonoporus spp., Etc.), and Cyclophyllidea (e.g., Mesocestoides spp., Anoplocephala spp., Paranoplocehala spp., Moniezia spp., Thysanosomsap. Thysaniezia spp., Avitellina spp., Stilesia spp., Cittotaenia spp., Andyra spp., 20 Bertiella spp., Taenia spp., Echinococcus spp., Hydatigera spp., Davainea spp., Raillietina spp., Hymenolepispp. spp., Echinocotyle spp., Diorchis spp., Dipylidium spp., Joyeuxiella spp., Diplopylidium spp., etc.); and others including parasites belonging to Acanthocephala and Linguatulida.
The endoparasite control agent of the present invention is effective not only against parasites that live in the body of an intermediate or final host, but also parasites that live in the body of a reservoir host. The compound represented by the general formula (I) of the present invention is effective at each stage of parasite development. For example, in the case of protozoa, the compound is effective against its cysts, pre-cystic forms and 30 trophozoites; schizonts and amoeboid forms in the asexual phase; gametocytes, gametes and zygotes in the sexual phase; sporozoites; etc. In the case of nematodes, the compound is effective against its eggs, larvae, and adults. The compound of the present invention is capable of not only fighting parasites in the living organism, but also even preventing parasitic infection through application in the environment as an infection route. For example, soil-borne infection, that is, infection from the soil of crops and parks; percutaneous infection from water
ί.
29/34 rivers, lakes, swamps, rice paddies, etc .; oral infection from feces of animals such as dogs and cats; oral infection from saltwater fish, freshwater fish, crustaceans, seafood, raw meat from domestic animals, etc .; infection from mosquitoes, horseflies, flies, cockroaches, mites, fleas, 5 lice, killer insects, thrombicidal mites, etc .; and the like can be prevented from occurring.
The endoparasite control agent of the present invention can be administered as a pharmaceutical product for treating or preventing parasitosis in humans and animals of non-human or avian mammalian species. The mode of administration can be oral or parenteral administration. In the case of oral administration, the endoparasite control agent of the present invention can be administered, for example, as a capsule, a tablet, a pill, a powder, a granulate, a fine granulate, a powder, a syrup, a preparation with enteric coating, a suspension or paste, or after mixing in a liquid drink or animal feed. In the case of parenteral administration, the endoparasite control agent of the present invention can be administered in a dosage form which allows for prolonged or percutaneous mucosal absorption, for example, as an injection, an infusion, a suppository, an emulsion, a suspension , a drop, 20 an ointment, a cream, a solution, a lotion, a spray, an aerosol, a poultice or a tape.
In the case where the endoparasite control agent of the present invention is used as a pharmaceutical product for humans and animals of non-human or avian mammal species, the ideal amount (effective amount) of the active ingredient varies with the purpose (treatment or prevention), the type of infectious parasite, the type and severity of the infection, the dosage form, etc., but in general, the daily oral dose is in the range of about 0.0001 to 10000 mg / kg of body weight and the parenteral daily dose is in the range of about 0.0001 to 10000 mg / kg of body weight, and such dose can be administered as a single dose 30 or in divided doses.
The concentration of the active ingredient in the endoparasite control agent of the present invention is generally about 0.001 to 100% by weight, preferably about 0.001 to 99% by weight, and more preferably about 0.005 to 20% by weight. The endoparasite control agent of the present invention can be a composition that can be directly
30/34 administered, or a highly concentrated composition that is used for administration after being diluted to an appropriate concentration.
In order to reinforce or complement the effect of the endoparasite control agent of the present invention, a combined use with any existing endoparasite control agent is possible. In such combined use, two or more active ingredients can be mixed and formulated into one preparation before administration, or two or more different preparations can be administered separately.
EXAMPLES
In the following, the present invention will be illustrated in detail through formulation examples and test examples of the endoparasite control agent of the present invention, but the scope of the present invention is not limited by the following formulation examples and test examples.
Formulation Example 1 (emulsion)
Ten parts of the carboxamide derivative represented by the general formula (I) of the present invention, 6 parts of Sorpol 355S (surfactant, manufactured by Toho Chemical Industry), and 84 parts of Solvesso 150 (manufactured by Exxon) are uniformly mixed with agitation to give an emulsion.
Formulation Example 2 (ointment)
A part of the carboxamide derivative represented by the general formula (I) of the present invention, 50 parts of white beeswax, and 49 parts of white petroleum jelly are mixed well to give an ointment.
Formulation Example 3 (tablet)
Two parts of the carboxamide derivative represented by the general formula (I) of the present invention, 10 parts of vegetable oil (olive oil), 3 parts of crystalline cellulose, 20 parts of white coal, and 65 parts of kaolin are well mixed and compressed in a pill.
Formulation Example 4 (injection)
Ten parts of the carboxamide derivative represented by the general formula (I) of the present invention, 10 parts of propylene glycol for use as a food additive, and 80 parts of vegetable oil (corn oil) are mixed well to give an injection.
Formulation Example 5 (solution)
Five parts of the carboxamide derivative represented by the general formula (I) of the present invention, 20 parts of surfactant, and 75 parts of ion-exchanged water are mixed well to give a solution.
31/34
Test Example 1 (In vitro measurement of inhibitory activity on succinatoubiquinone reductase (mitochondrial complex II) from Ascarís suum)
To a solution containing 50 mM potassium phosphate (pH 7.4) and 0.1% (w / v) sucrose monolaurate, an ubiquinone-2 electron acceptor (UQ2) was added at a final concentration of 60 pM, and to the mixture it was allowed to stay at 25 ° C for 20 minutes. To this, potassium cyanide (final concentration: 2 mM) and mitochondria prepared from adult Ascarís suum muscle were added, and a complete mixture was made. At aliquots of the mixture, an inhibitor to be tested was added at various concentrations, and the mixtures were allowed to stay at 10 25 ° C for 3 minutes. The enzymatic reaction was initiated by the addition of potassium succinate (final concentration: 10 mM). The enzymatic activity was calculated based on the measurement of change in absorbance at 278 nm of UQ2 (ε = 1.5x10 ⁴ M ' ¹ cm' ¹ ), and IC50 was determined from the graph of the percentage of inhibition against the inhibitor concentration.
Test Example 2 (in vitro measurement of inhibitory activity in porcine succinatoubiquinone reductase (mitochondrial complex II))
To a solution containing 50 mM potassium phosphate (pH 7.4) and 0.1% (w / v) sucrose monolaurate, an ubiquinone-2 electron acceptor (UQ2) was added to a final concentration of 60 μΜ, and the mixture was allowed to stay at 20 25 ° C for 20 minutes. To this, potassium cyanide (final concentration: 2 mM) and mitochondria prepared from porcine heart muscle were added, and a complete mixture was made. At aliquots of the mixture, an inhibitor to be tested was added at various concentrations, and the mixtures were allowed to stand at 25 ° C for 3 minutes. The enzymatic reaction was initiated by the addition of potassium succinate 25 (final concentration: 10 mM). The enzymatic activity was calculated based on the measurement of absorbance change at 278 nm of UQ2 (ε = 1.5x10 ⁴ M ' ¹ cm' ¹ ), and IC ₅₀ was determined from the graph of the percentage of inhibition against the inhibitor concentration .
The results are shown in Table 5. In the table, it indicates “not tested 30”, and “IC ₅₀ value of Ascarís suum (A)” indicates IC 50 value (50% inhibitory concentration) for inhibition of succinate-ubiquinone reductase ( mitochondrial complex II) of Ascarís suum. From the extent of inhibition of this respiratory enzyme, the parasite control activity can be estimated. "IC ₅₀ value of swine mitochondria (B)" indicates an IC50 value for inhibition of succinate35 ubiquinone reductase (mitochondrial complex II) of the host pig. From the extent of inhibition of this respiratory enzyme, the influence on the host can
32/34 be estimated. A higher B / A selectivity index indicates greater security for the host.
Table 6
V <· *
Number ofCompound IC50 value ofAscaris suum (A) Swine mitochondria IC50 value (B) B / A selectivity 1-3 1.21 nM without inhibition at 90 μΜ > 27000 1-16 3.34 nM without inhibition at 90 μΜ > 74400 1-27 1.69 nM without inhibition at 90 μΜ > 53300 1-32 2.15 nM without inhibition at 9 μΜ > 4190 1-64 9 nM without inhibition at 9 μΜ > 9150 1-81 4.8 nM 10% to 90 μΜ > 18800 1-88 12 nM - Not calculated 1-110 4.07 nM without inhibition at 10 μΜ > 2460 1-111 13.1 nM without inhibition at 90 μΜ > 6870 1-112 1.50 nM without inhibition at 90 μΜ > 60000 2-1 5.47 nM 111 μΜ 20295 2-3 127 nM without inhibition at 90 μΜ > 709 2-4 70.5 nM without inhibition at 90 μΜ > 1280 2-5 3.83 nM without inhibition at 9 μΜ > 2350 2-6 28.3 nM 10% to 90 μΜ > 3180 2-7 14 nM without inhibition at 90 μΜ > 6430 2-8 38.2 nM without inhibition at 90 μΜ > 2360 3-7 1.60 nM 90 μΜ 56250 4-1 3.44 nM - Not calculated 4-2 5.15 nM - Not calculated 4-3 1.98 nM - Not calculated 4-4 8.36 nM 16% at 90 μΜ > 10770 4-5 6.07 nM 11% to 90 μΜ > 14830 4-6 8.34 nM without inhibition at 9 μΜ > 1079 4-7 1.78 nM 103 μΜ 57870 4-8 2.61 nM 5% to 9 μΜ > 3448
As was clear from the results in Table 5, the carboxamide derivatives represented by the general formula (I) of the present invention and their salts showed a strong inhibitory activity in the parasitic succinate-ubiquinone reductase (mitochondrial complex II) (IC ₅₀ values: 1.21 to 127 nM), but
33/34 hardly affected the succinate-ubiquinone reductase activity (mitochondrial complex II) of the host pig (selectivity more than 1,000 greater). Therefore, the endoparasite control agent of the present invention is not only highly active in parasite control, but also highly safe for the host.
Test Example 3 (in vivo activity in Haemonchus contortus)
The test was conducted according to the larval migration inhibition assay (LMIA: Demeler et al., 2010). A larval suspension was prepared to contain 100 to 120 third-stage Haemonchus contortus larvae for 10 each 20 pL, and then 20 pL of the larval suspension was added to each well in a breeding plate to which compound solutions adjusted to predetermined concentrations were previously added at 1780 pL / well each. The breeding plate was kept for breeding at 28 ° C for 24 hours. Meanwhile, to a plate for observation of larval migration, 400 pL of 15 a 1.5% agar solution was added and allowed to stand until coagulation.
Then, the larvae were allowed to migrate through a sieve from the reproduction plate to the plate for observation of migration, and the plates were kept for reproduction at 28 ° C for another 24 hours. The larvae that had migrated, and the larvae that had not migrated were counted, the percentage of inhibition of migration was calculated, and the activity was classified based on the following criteria. All samples were tested in duplicate, and the results are shown in Table 7. In the table, it says “not tested”.
Percentage of 100% migration inhibition: A
40 to 69%: B to 39%: C lower than 10%: D
Table 7
Number ofCompound Concentration (ppm) 100 10 1 0.1 1-16 B ç ç ç 1-32 - B ç ç 2-1 - - I B ç 2-6 - ç Ç ç
34/34
3-7 B Ç Ç Ç 4-1 - Ç Ç Ç 4-7 B Ç Ç Ç
As was clear from the results in Table 7, the compounds that proved to have, in the in vitro test described above, a strong activity showed a strong activity in the in vivo test as well, and therefore the compound of the present invention is effective as an endoparasite control.

权利要求:
Claims (8)
[1]
1. Composition for use in the control of endoparasites for oral or parenteral administrationAgent-of-control-of-endoparasite characterized by the fact that ^ comprises a carboxamide derivative represented by the general formula (I):
The {where A represents a (C1-C8) alkylene group optionally substituted by a halogen atom, a (C1-C6) alkyl group and / or a (C3-C6) cycloalkyl group; an alkylene group (C1-C8) which is optionally substituted by a halogen atom, an alkyl group (C1C6) and / or a cycloalkyl group (C3-C6) and is modified by incorporating, in the carbon chain, at least a heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and -N (R) - (where R represents a hydrogen atom, a (C1-C6) alkyl group, a cycloalkyl group (C3-C6), an alkylcarbonyl group (C1-C6) or an alkoxycarbonyl group (C1-C6)); an alkenylene (C2-C8) group optionally substituted by a halogen atom, a (C1-C6) alkyl group and / or a (C3-C6) cycloalkyl group; an alkenylene group (C2-C8) which is optionally substituted by a halogen atom, an alkyl group (C1C6) and / or a cycloalkyl group (C3-C6) and is modified by incorporating, in the carbon chain, at least a heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and -N (R) (where R is as defined above); an alkynylene group (C2-C8) optionally substituted by a halogen atom, a (C1C6) alkyl group and / or a (C3-C6) cycloalkyl group; or an alkynylene group (C2-C8) which is optionally substituted by a halogen atom, an alkyl group (C1-C6) and / or a cycloalkyl group (C3-C6) and is modified by incorporation, in the carbon chain, of at least one heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and -N (R) - (where R is as defined above), and in each case, A can form a cyclic structure, where possible,
E represents a hydrogen atom; a (C1-C6) alkyl group; a cycloalkyl group (C3-C6); a (C1-C6) alkoxy (C1-C6) alkyl group; a group
Petition 870190055407, of 6/14/2019, p. 21/38
[2]
2/6 (C1-C6) alkylcarbonyl; or an alkoxycarbonyl group (C1-C6), each X can be the same or different, and represents a halogen atom; a cyan group; a nitro group; a (C1-C6) alkyl group optionally substituted by a halogen atom; an alkoxy group (C1-C6) optionally substituted by a halogen atom; an alkylthio group (C1-C6) optionally substituted by a halogen atom; a (C1-C6) alkylsulfinyl group optionally substituted by a halogen atom; or a (C1-C6) alkylsulfonyl group optionally substituted by a halogen atom, m represents an integer from 0 to 5, each Y can be the same or different, and represents a halogen atom; a cyan group; a nitro group; a hydroxyl group; a (C1-C6) alkyl group optionally substituted by a halogen atom; an alkenyl group (C2-C6) optionally substituted by a halogen atom; an alkynyl group (C2-C6) optionally substituted by a halogen atom; an alkoxy group (C1-C6) optionally substituted by a halogen atom; an (C1-C6) alkoxy (C1-C6) alkoxy group; an alkenyloxy group (C2-C6) optionally substituted by a halogen atom; an alkynyloxy group (C2-C6) optionally substituted by a halogen atom; an alkylthio group (C1-C6) optionally substituted by a halogen atom; a (C1-C6) alkylsulfinyl group optionally substituted by a halogen atom; a (C1-C6) alkylsulfonyl group optionally substituted by a halogen atom; an alkoxycarbonyl group (C1-C6); an (C1-C6) alkoxylimino (C1-C3) alkyl group; a trialkylsilyl group (C3-C30); a monoalkylsufonylamino group (C1-C6) optionally substituted by a halogen atom; a phenyl group optionally substituted by one or more substituents selected from substituents in group B; a phenoxy group optionally substituted by one or more substituents selected from substituents in group B; a heterocyclic group optionally substituted by one or more substituents selected from substituents in group B; or a heterocycloxy group optionally substituted by one or more substituents selected from group B substituents, the group B substituents are a halogen atom; a cyan group; a nitro group; a (C1-C6) alkyl group optionally substituted by a halogen atom; an alkenyl group (C2-C6) optionally
Petition 870190055407, of 6/14/2019, p. 22/38
[3]
3/6 replaced by a halogen atom; an alkynyl group (C2-C6) optionally substituted by a halogen atom; an alkoxy group (C1-C6) optionally substituted by a halogen atom; an alkenyloxy group (C2-C6) optionally substituted by a halogen atom; an alkynyloxy group (C2-C6) optionally substituted by a halogen atom; an alkylthio group (C1-C6) optionally substituted by a halogen atom; a (C1-C6) alkylsulfinyl group optionally substituted by a halogen atom; a (C1-C6) alkylsulfonyl group optionally substituted by a halogen atom; an alkoxycarbonyl group (C1-C6); and a (C1-C6) alkoxy (C1-C3) alkyl group, n represents an integer from 0 to 5, with the proviso that when n is an integer from 2 to 5, two adjacent Y groups can be joined to forming a (C3-C5) alkylene group; an alkenylene group (C3-C5); an (C2-C4) alkyleneoxy group; or a (C1-C3) alkylenedioxy group optionally substituted by a halogen atom, and
Z represents a nitrogen atom; CH; or CY (where Y is as defined above)}, or a salt thereof as an active ingredient.
2. Composition for use in the control of endoparasites for oral or parenteral administrationAgent of control of endoparasites, according to claim 1, characterized by the fact that
A represents a (C1-C8) alkylene group optionally substituted by a halogen atom, a (C1-C6) alkyl group and / or a (C3-C6) cycloalkyl group; or a (C1-C8) alkylene group which is optionally substituted by a halogen atom, a (C1-C6) alkyl group and / or a (C3-C6) cycloalkyl group and is modified by incorporation into the carbon chain, of at least one heteroatom selected from an oxygen atom, a sulfur atom, -SO-, -SO2- and -N (R) - (where R represents a hydrogen atom, a (C1-C6) alkyl group ), a cycloalkyl (C3-C6) group, an alkylcarbonyl (C1-C6) group or an alkoxycarbonyl (C1-C6) group).
3. Composition for use in the control of endoparasites for oral or parenteral administrationEndoparasite control agent, according to claim 1, characterized by the fact that
A represents a (C1-C8) alkylene group optionally substituted by a (C1-C6) alkyl group and / or a (C3-C6) cycloalkyl group; -CR ¹ (R ² )
Petition 870190055407, of 6/14/2019, p. 23/38
[4]
4/6
CR ³ (R ⁴ ) -Q- (where R ¹ , R ² , R ³ and R ⁴ can be the same or different from each other, and represent a hydrogen atom, a (C1C6) alkyl group or a cycloalkyl group (C3-C6), or R ¹ , R ² , R ³ and R ⁴ can join in any combination to form a cycloalkane (C3-C6), and Q represents an oxygen atom, a sulfur atom, -SO- , -SO2- or -N (R) - (where R represents a hydrogen atom, a (C1-C6) alkyl group, a (C3-C6) cycloalkyl group, a (C1-C6) alkylcarbonyl group or a group alkoxycarbonyl (C1-C6))); or -CR ¹ (R ² ) -CR ³ (R ⁴ ) -CR ⁵ (R ⁶ ) -Q- (where R ¹ , R ² , R ³ , R ⁴ and Q are as defined above, and R ⁵ and R ⁶ can be the same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group or a (C3-C6) cycloalkyl group, or R ¹ , R ² , R ³ , R ⁴ , R ⁵ and R ⁶ can join in any combination to form a cycloalkane (C3C6)).
4. Composition for use in the control of endoparasites for oral or parenteral administrationAgent of control of endoparasites, according to claim 1, characterized by the fact that
A represents a (C1-C8) alkylene group optionally substituted by a (C1-C6) alkyl group and / or a (C3-C6) cycloalkyl group; -CR ¹ (R ² ) CR ³ (R ⁴ ) -Q- (where R ¹ , R ² , R ³ and R ⁴ can be the same or different from each other, and represent a hydrogen atom, an alkyl group (C1C6) or a cycloalkyl group (C3-C6), or R ¹ , R ² , R ³ and R ⁴ can join in any combination to form a cycloalkane (C3-C6), and Q represents an oxygen atom, a sulfur atom, -SO-, -SO2- or -N (R) - (where R represents a hydrogen atom, a (C1-C6) alkyl group, a (C3-C6) cycloalkyl group, an alkylcarbonyl group ( C1-C6) or an (C1-C6) alkoxycarbonyl group)); or -CR ¹ (R ² ) -CR ³ (R ⁴ ) -CR ⁵ (R ⁶ ) -Q- (where R ¹ , R ² , R ³ , R ⁴ and Q are as defined above, and R ⁵ and R ⁶ can be the same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group or a (C3-C6) cycloalkyl group, or R ¹ , R ² , R ³ , R ⁴ , R ⁵ and R ⁶ can join in any combination to form a cycloalkane (C3C6)),
E represents a hydrogen atom; a (C1-C6) alkyl group; a (C1-C6) alkylcarbonyl group; or an alkoxycarbonyl group (C1-C6), each X can be the same or different, and represents a halogen atom; a (C1-C6) alkyl group optionally substituted by a halogen atom; an alkoxy group (C1-C6) optionally substituted by a
Petition 870190055407, of 6/14/2019, p. 24/38
[5]
5/6 halogen atom; or an alkylthio group (C1-C6) optionally substituted by a halogen atom, m represents 1 or 2, each Y can be the same or different, and represents a halogen atom; a hydroxyl group; a (C1-C6) alkyl group optionally substituted by a halogen atom; an alkoxy group (C1-C6) optionally substituted by a halogen atom; an (C1-C6) alkoxy (C1-C6) alkoxy group; an alkenyloxy group (C2-C6) optionally substituted by a halogen atom; a monoalkylsufonylamino group (C1-C6) optionally substituted by a halogen atom; a phenyl group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group optionally substituted by a halogen atom, and an alkoxy group (C1- C6) optionally substituted by a halogen atom; a phenoxy group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group optionally substituted by a halogen atom, and an alkoxy group (C1- C6) optionally substituted by a halogen atom; a heterocyclic group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group optionally substituted by a halogen atom, and an alkoxy group (C1- C6) optionally substituted by a halogen atom; or a heterocycloxy group optionally substituted by one or more substituents selected from a halogen atom, a cyano group, a nitro group, a (C1-C6) alkyl group optionally substituted by a halogen atom, and an alkoxy group (C1 -C6) optionally substituted by a halogen atom, n represents an integer from 0 to 3, with the proviso that when n is 2 or 3, two adjacent Y groups can join to form a (C2-C4) alkyleneoxy group or a (C1-C3) alkylenedioxy group optionally substituted by a halogen atom, and
Z represents a nitrogen atom; CH; or CY (where Y is as defined above).
5. Composition for use in the control of endoparasites for
Petition 870190055407, of 6/14/2019, p. 25/38
[6]
6/6 oral or parenteral administrationEndoparasite control agent, according to claim 1, characterized by the fact that,
A represents a (C1-C5) alkylene group optionally substituted by a (C1-C6) alkyl group and / or a (C3-C6) cycloalkyl group; -CR ¹ (R ² ) CR ³ (R ⁴ ) -Q- (where R ¹ , R ² , R ³ and R ⁴ can be the same or different from each other, and represent a hydrogen atom, an alkyl group (C1C6) or a cycloalkyl group (C3-C6), and Q represents an oxygen atom or a sulfur atom); or -CR ¹ (R ² ) -CR ³ (R ⁴ ) -CR ⁵ (R ⁶ ) -Q- (where R ¹ , R ² , R ³ , R ⁴ and Q are as defined above, and R ⁵ and R ⁶ can be the same or different from each other, and represent a hydrogen atom, a (C1-C6) alkyl group or a (C3-C6) cycloalkyl group),
E represents a hydrogen atom, each X can be the same or different, and represents a halogen atom or a (C1-C6) alkyl group optionally substituted by a halogen atom, m represents 1, each Y can be the same or different, and represents a halogen atom or a (C1-C6) alkyl group optionally substituted by a halogen atom, n represents an integer from 1 to 3, and
Z represents a nitrogen atom; CH; or CY (where Y is as defined above).
67 ---- Method — to — control — endoparasites, —characterized — for comprising administering orally or parenterally an effective amount of the endoparasite control agent according to any one of claims 1 to 5 to a non-human mammal or a bird.
[7]
7 ---- Method — to — control — endoparasites, —characterized — for comprising administering orally or parenterally an effective amount of the endoparasite control agent according to any one of claims 1 to 5 to a non-human mammal.
[8]
8 ---- Method according to claim 7, characterized by the fact that the non-human mammal is a domestic animal.

类似技术:

---

公开号 | 公开日 | 专利标题

---

ES2625990T3|2017-07-21|Endoparasite control agent

---

US10017490B2|2018-07-10|Endoparasite control agent and method for using the same

---

AU2013310074B2|2018-07-05|Endoparasite control agent

---

AU2015224926A1|2016-09-08|Endoparasite control agent

---

AU2015224925A1|2016-09-08|Endoparasite control agent

---

NZ613343B2|2016-01-06|Internal parasiticide

---

BR112015000128B1|2021-11-23|ENDOPARASITE CONTROL AGENT FOR A NON-HUMAN MAMMALS OR A BIRD

同族专利:

---

公开号 | 公开日

---

UA114287C2|2017-05-25|

---

CN108524480A|2018-09-14|

---

CN103415288B|2018-04-03|

---

AU2012224015B2|2017-04-13|

---

JP5973989B2|2016-08-23|

---

KR20140011341A|2014-01-28|

---

CL2013002507A1|2014-05-23|

---

US20140088157A1|2014-03-27|

---

MX2013009957A|2013-12-06|

---

CA2828060C|2018-11-06|

---

AU2012224015A1|2013-09-26|

---

ZA201305979B|2014-10-29|

---

ES2625990T3|2017-07-21|

---

EP2682115A1|2014-01-08|

---

BR112013021337A2|2016-11-01|

---

US9447042B2|2016-09-20|

---

RU2013144215A|2015-04-10|

---

JPWO2012118139A1|2014-07-07|

---

KR101856577B1|2018-05-10|

---

EP2682115A4|2014-11-26|

---

CN103415288A|2013-11-27|

---

RU2596788C2|2016-09-10|

---

NZ613343A|2015-09-25|

---

CA2828060A1|2012-09-07|

---

WO2012118139A1|2012-09-07|

---

MX345339B|2017-01-25|

---

EP2682115B1|2017-04-19|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

NL169174C|1976-07-12|1982-06-16|Nihon Nohyaku Co Ltd|PROCESS FOR PREPARING AN AGRICULTURAL AND GARDEN FUNGICIDE PREPARATION, PROCESS FOR CONTROLLING DISEASES OF AGRICULTURAL AND GARDENING CROPS BY USING THIS PREPARATION, AND PROCESS FOR PREPARING A PETROLEUM ACID ANIDID.|

---

JPS5645907B2|1976-07-12|1981-10-29|

---

KR890006573A|1987-10-26|1989-06-14|메리 엔 터커|N-phenylalkylbenzamide fungicides|

---

DE4400464A1|1994-01-11|1995-07-13|Bayer Ag|Endoparasiticidal agents|

---

GB9601128D0|1995-08-11|1996-03-20|Pfizer Ltd|Parasiticidal compounds|

---

AU3458802A|2000-12-20|2002-07-01|Novartis Ag|Organic compounds|

---

TWI261053B|2001-12-06|2006-09-01|Novartis Ag|Amidoacetonitrile compounds, their preparation, compositions and use as pesticides|

---

CN1319946C|2002-08-12|2007-06-06|拜尔农科股份有限公司|Novel 2-pyridylethylbenzamide derivative|

---

WO2007060162A1|2005-11-22|2007-05-31|Bayer Cropscience Sa|New n-benzamide derivatives|

---

TWI435863B|2006-03-20|2014-05-01|Nihon Nohyaku Co Ltd|N-2- arylethylcarboxamide derivative and pest controlling|

---

WO2008003745A1|2006-07-06|2008-01-10|Bayer Cropscience Sa|N- benzamide derivatives and their use as fungicides|

---

WO2008003746A1|2006-07-06|2008-01-10|Bayer Cropscience Sa|N- carboxamide derivatives, their process of preparation and their use as fungicides|

---

CL2008000512A1|2007-02-22|2008-08-29|Bayer Cropscience Sa|COMPOUNDS DERIVED FROM N- CARBOXAMIDE; PROCEDURE FOR PREPARATION OF SUCH COMPOUNDS; FUNGICIDE COMPOSITION; AND METHOD FOR FIGHTING PREVENTIVE OR CURATIVE FITOPATOGEN MUSHROOMS.|

---

WO2008101975A2|2007-02-22|2008-08-28|Bayer Cropscience Sa|New n-benzamide derivatives|

---

CA2682156C|2007-04-12|2012-03-20|Nihon Nohyaku Co., Ltd.|Nematicidal agent composition and method of using the same|

---

US8324263B2|2007-07-26|2012-12-04|Syngenta Crop Protection, Llc|Microbiocidally active carboxamides|

---

GB0807140D0|2008-04-18|2008-05-21|Syngenta Participations Ag|Novel microbiocides|

---

GB0904658D0|2009-03-18|2009-04-29|Syngenta Crop Protection Ag|Novel microbiocides|

---

ES2585816T3|2009-03-25|2016-10-10|Bayer Cropscience Ag|Combinations of nematicidal active ingredients comprising fluopiram and Bacillus firmus|

---

EP2782572A1|2011-11-25|2014-10-01|Bayer Intellectual Property GmbH|Use of fluopyram for controlling endoparasites|EP2353547B1|2008-06-26|2018-01-17|Nobelpharma Co., Ltd.|Agent for regenerating tympanic membrane or external auditory canal|

---

BR112014010714A2|2011-11-02|2017-05-02|Bayer Ip Gmbh|compounds with nematicidal activity|

---

AU2012331285A1|2011-11-02|2014-04-17|Bayer Intellectual Property Gmbh|Compounds with nematicidal activity|

---

BR112014010628A2|2011-11-04|2017-04-25|Syngenta Ltd|pesticide compounds|

---

EP2782572A1|2011-11-25|2014-10-01|Bayer Intellectual Property GmbH|Use of fluopyram for controlling endoparasites|

---

BR112014012589A2|2011-11-25|2017-06-20|Bayer Intelectual Property Gmbh|use of aryl and hetaryl carboxamides as endoparasiticides|

---

UY34997A|2012-08-30|2014-03-31|Nihon Nohyaku Co Ltd|ENDOPARASIT CONTROL AGENT AND METHOD FOR USE|

---

UY34996A|2012-08-30|2014-03-31|Nihon Nohyaku Co Ltd|ENDOPARASIT CONTROL AGENT|

---

TW201427947A|2012-10-12|2014-07-16|Lundbeck & Co As H|Cyclic amines|

---

TWI598325B|2012-10-12|2017-09-11|Ｈ 朗德貝克公司|Benzamides|

---

EP2730570A1|2012-11-13|2014-05-14|Bayer CropScience AG|Pyridyloxyal alkyl carboxamides and their use as endoparasiticides and nematicide|

---

TW201507722A|2013-04-30|2015-03-01|Bayer Cropscience Ag|N-carboxamides as nematicides and endoparasiticides|

---

TWI646092B|2013-08-26|2019-01-01|拜耳作物科學股份有限公司|Compound with insecticidal activity|

---

UY35772A|2013-10-14|2015-05-29|Bayer Cropscience Ag|NEW PESTICIDED COMPOUNDS|

---

AR098475A1|2013-11-26|2016-06-01|Bayer Cropscience Ag|PESTICIDE COMPOUNDS AND USES|

---

EP3109234A4|2014-02-18|2017-07-05|Nissan Chemical Industries, Ltd.|Alkynylpyridine-substituted amide compound and noxious organism control agent|

---

AU2015224926B2|2014-03-05|2019-07-18|Nihon Nohyaku Co., Ltd.|Endoparasite control agent|

---

CN106029069B|2014-03-05|2020-01-24|国立大学法人东京大学|Endoparasite control agent|

---

UY36196A|2014-07-25|2016-02-29|Bayer Animal Health Gmbh|COMPOUNDS TO USE IN ANTIHELMINTIC TREATMENT|

---

WO2016066574A1|2014-10-28|2016-05-06|Bayer Animal Health Gmbh|Compounds for use in anthelminthic treatment|

---

WO2016066636A1|2014-10-29|2016-05-06|Bayer Cropscience Aktiengesellschaft|N-carboxamides as fungicides|

---

EP3227274B1|2014-12-02|2019-07-03|Bayer CropScience Aktiengesellschaft|Bicyclic compounds as pest controllers|

---

US11174325B2|2017-01-12|2021-11-16|Carnegie Mellon University|Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes|

---

RU2673677C1|2017-10-17|2018-11-29|ФАНО России, Федеральное государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт фундаментальной и прикладной паразитологии животных и растений им. К.И. Скрябина |Agent for disinvasion against buxtonella sulcata in cattle|

---

USD888149S1|2018-01-04|2020-06-23|Samsung Electronics Co., Ltd.|Type font|

法律状态:
2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-03-19| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-04-16| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|

---

2019-07-23| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2019-09-03| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/03/2012, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/03/2012, OBSERVADAS AS CONDICOES LEGAIS |

优先权:

---

申请号 | 申请日 | 专利标题

---

JP2011045042|2011-03-02|

---

PCT/JP2012/055190|WO2012118139A1|2011-03-02|2012-03-01|Internal parasiticide|

---